BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24710762)

  • 1. Osteonecrosis in paediatric patients with acute lymphoblastic leukaemia treated on Co-ALL-07-03 trial: a single centre analysis.
    Kuhlen M; Moldovan A; Krull K; Meisel R; Borkhardt A
    Klin Padiatr; 2014 May; 226(3):154-60. PubMed ID: 24710762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia.
    te Winkel ML; Pieters R; Hop WC; de Groot-Kruseman HA; Lequin MH; van der Sluis IM; Bökkerink JP; Leeuw JA; Bruin MC; Egeler RM; Veerman AJ; van den Heuvel-Eibrink MM
    J Clin Oncol; 2011 Nov; 29(31):4143-50. PubMed ID: 21947829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
    Mattano LA; Devidas M; Nachman JB; Sather HN; Hunger SP; Steinherz PG; Gaynon PS; Seibel NL;
    Lancet Oncol; 2012 Sep; 13(9):906-15. PubMed ID: 22901620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia.
    Aricò M; Boccalatte MF; Silvestri D; Barisone E; Messina C; Chiesa R; Santoro N; Tamaro P; Lippi A; Gallisai D; Basso G; De Rossi G;
    Haematologica; 2003 Jul; 88(7):747-53. PubMed ID: 12857552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL).
    Kotecha RS; Powers N; Lee SJ; Murray KJ; Carter T; Cole C
    Pediatr Blood Cancer; 2010 Jul; 54(7):934-40. PubMed ID: 20127847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia.
    Elmantaser M; Stewart G; Young D; Duncan R; Gibson B; Ahmed SF
    Arch Dis Child; 2010 Oct; 95(10):805-9. PubMed ID: 20576660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia.
    Niinimäki RA; Harila-Saari AH; Jartti AE; Seuri RM; Riikonen PV; Pääkkö EL; Möttönen MI; Lanning M
    J Clin Oncol; 2007 Apr; 25(12):1498-504. PubMed ID: 17442991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group.
    Mattano LA; Sather HN; Trigg ME; Nachman JB
    J Clin Oncol; 2000 Sep; 18(18):3262-72. PubMed ID: 10986059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia.
    Mogensen SS; Harila-Saari A; Mäkitie O; Myrberg IH; Niinimäki R; Vestli A; Hafsteinsdottir S; Griškevicius L; Saks K; Hallböök H; Retpen J; Helt LR; Toft N; Schmiegelow K; Frandsen TL;
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27300. PubMed ID: 29943905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97.
    Escherich G; Horstmann MA; Zimmermann M; Janka-Schaub GE;
    Leukemia; 2010 Feb; 24(2):298-308. PubMed ID: 20016530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95.
    Bürger B; Beier R; Zimmermann M; Beck JD; Reiter A; Schrappe M
    Pediatr Blood Cancer; 2005 Mar; 44(3):220-5. PubMed ID: 15514916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow oedema and aseptic osteonecrosis in children and adolescents with acute lymphoblastic leukaemia or non-Hodgkin-lymphoma treated with hyperbaric-oxygen-therapy (HBO): an approach to cure? -- BME/AON and hyperbaric oxygen therapy as a treatment modality.
    Bernbeck B; Christaras A; Krauth K; Lentrodt S; Strelow H; Schaper J; Janssen G; Mödder U; Göbel U
    Klin Padiatr; 2004; 216(6):370-8. PubMed ID: 15565553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
    Veerman AJ; Kamps WA; van den Berg H; van den Berg E; Bökkerink JP; Bruin MC; van den Heuvel-Eibrink MM; Korbijn CM; Korthof ET; van der Pal K; Stijnen T; van Weel Sipman MH; van Weerden JF; van Wering ER; van der Does-van den Berg A;
    Lancet Oncol; 2009 Oct; 10(10):957-66. PubMed ID: 19747876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the General Practice Research Database.
    Högler W; Wehl G; van Staa T; Meister B; Klein-Franke A; Kropshofer G
    Pediatr Blood Cancer; 2007 Jan; 48(1):21-7. PubMed ID: 16317756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avascular necrosis--an antineoplastic-treatment-related toxicity: the experiences of two institutions.
    Sawicka-Zukowska M; Kajdas L; Muszynska-Roslan K; Krawczuk-Rybak M; Sonta-Jakimczyk D; Szczepanski T
    Pediatr Hematol Oncol; 2006 Dec; 23(8):625-9. PubMed ID: 17065138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
    Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
    Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bony morbidity in children treated for acute lymphoblastic leukemia.
    Strauss AJ; Su JT; Dalton VM; Gelber RD; Sallan SE; Silverman LB
    J Clin Oncol; 2001 Jun; 19(12):3066-72. PubMed ID: 11408503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, risk factors, and treatment outcome of symptomatic osteonecrosis in Taiwanese children with acute lymphoblastic leukemia: a retrospective cohort study of 245 patients in a single institution.
    Chen SH; Chang TY; Jaing TH; Lee MS; Wang CJ; Hung IJ; Yang CP
    Int J Hematol; 2015 Jul; 102(1):41-7. PubMed ID: 25840770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate--a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
    Pichler H; Reismüller B; Steiner M; Dworzak MN; Pötschger U; Urban C; Meister B; Schmitt K; Panzer-Grümayer R; Haas OA; Attarbaschi A; Mann G;
    Br J Haematol; 2013 May; 161(4):556-65. PubMed ID: 23480776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and risk factors of cataract after chemotherapy with or without central nervous system irradiation for childhood acute lymphoblastic leukaemia: an LEA study.
    Alloin AL; Barlogis V; Auquier P; Contet A; Poiree M; Demeocq F; Herrmann I; Villes V; Bertrand Y; Plantaz D; Kanold J; Chastagner P; Chambost H; Sirvent N; Michel G
    Br J Haematol; 2014 Jan; 164(1):94-100. PubMed ID: 24116693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.